The G6PD Drugs-to-Avoid List: A Structured Reference for Patients, Caregivers, and Clinicians
For the estimated 400 million people worldwide living with glucose-6-phosphate dehydrogenase (G6PD) deficiency — including millions of Americans — a routine prescription can become a medical emergency. The enzyme G6PD plays a critical role in protecting red blood cells from oxidative damage. When that enzyme is absent or insufficient, certain drugs can trigger the rapid destruction of red blood cells, a condition known as hemolytic anemia.
Knowing which drugs to avoid is not optional for G6PD patients. It is a fundamental pillar of safe, informed self-advocacy. This reference is designed to be consulted regularly, shared with providers, and kept accessible during any medical encounter.
Important Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult your physician or pharmacist before starting, stopping, or changing any medication. Drug safety classifications for G6PD patients can vary by enzyme variant and individual severity. Never discontinue a prescribed medication without speaking to your provider first.
Why Certain Drugs Trigger Hemolysis in G6PD Patients
G6PD is an enzyme that helps red blood cells generate a molecule called NADPH, which in turn maintains glutathione — the cell's primary antioxidant defense. When a G6PD-deficient individual is exposed to an oxidative stressor, such as certain drugs, the red blood cells cannot neutralize the oxidative damage. The result is hemolysis: the premature rupture of red blood cells.
Symptoms of drug-induced hemolysis include sudden fatigue, jaundice, dark or tea-colored urine, shortness of breath, rapid heart rate, and pallor. In severe cases, this can escalate to acute hemolytic anemia requiring emergency hospitalization and blood transfusion.
The risk is not uniform. Patients with more severe G6PD variants — such as Class I deficiency — face greater risk than those with milder variants. However, no G6PD-deficient individual should assume they are immune to drug-induced hemolysis without confirmed clinical guidance.
High-Risk Medications: The Core Drugs-to-Avoid List
The following drug categories and specific agents are most frequently associated with hemolytic episodes in G6PD-deficient individuals. This list is informed by established pharmacological literature, including guidelines from the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), and peer-reviewed hematology research.
Antimalarial Medications
This category carries some of the highest hemolytic risk for G6PD patients:
- Primaquine — Among the most documented triggers of hemolysis in G6PD deficiency. Its use is contraindicated in most G6PD-deficient individuals.
- Chloroquine — Generally considered lower risk than primaquine but still flagged for caution, particularly at higher doses.
- Hydroxychloroquine — Widely prescribed for autoimmune conditions such as lupus and rheumatoid arthritis. G6PD patients using this drug should do so only under close medical supervision.
- Tafenoquine — A newer antimalarial with significant hemolytic potential; G6PD testing is now required before prescribing in the US.
- Quinine — Associated with hemolysis in G6PD-deficient patients; also found historically in some tonic waters at pharmacological levels.
Antibiotics and Sulfonamides
- Dapsone — Used to treat leprosy, dermatitis herpetiformis, and some Pneumocystis infections. Carries high hemolytic risk.
- Sulfamethoxazole (found in Bactrim/TMP-SMX) — Commonly prescribed for urinary tract infections and other bacterial infections; G6PD patients must use with caution.
- Nitrofurantoin — A urinary antibiotic frequently prescribed for UTIs. Contraindicated or used with significant caution in G6PD-deficient patients.
- Nalidixic acid — An older quinolone antibiotic with documented hemolytic risk.
- Ciprofloxacin and other fluoroquinolones — Generally considered lower risk but should be used cautiously in severe deficiency variants.
Analgesics and Antipyretics
- Aspirin (high doses) — At standard low doses (81 mg), aspirin is often considered acceptable for many G6PD patients, but higher doses carry oxidative risk.
- Phenacetin — Now largely withdrawn from the US market, but occasionally encountered in compounded formulations.
- Acetaminophen (Tylenol) — Generally considered safe at standard doses for most G6PD patients, but overuse or high doses may pose risk in severe variants.
Cardiovascular Medications
- Quinidine — An antiarrhythmic agent associated with hemolytic anemia in G6PD patients.
- Hydralazine — Used for hypertension; some evidence of hemolytic risk.
Other Agents of Concern
- Rasburicase — Used to treat tumor lysis syndrome; absolutely contraindicated in G6PD deficiency due to severe hemolytic risk. The FDA mandates G6PD screening before use.
- Methylene blue — Commonly used as an antidote for methemoglobinemia. Paradoxically ineffective and potentially harmful in G6PD-deficient patients.
- Phenazopyridine (AZO) — A urinary analgesic available over-the-counter; associated with hemolysis in G6PD patients and should generally be avoided.
- Naphthalene — Found in some mothballs; not a drug but a significant chemical trigger worth noting for household safety.
Medications Generally Considered Safer
Several common medications are typically considered low-risk for the majority of G6PD-deficient individuals, including:
- Acetaminophen at standard doses
- Ibuprofen at standard doses (though NSAIDs carry other risks)
- Penicillin-based antibiotics
- Most cephalosporins
- Azithromycin
However, "generally safer" does not mean risk-free for every individual. Variant severity, dose, and concurrent health conditions all influence actual risk. Always confirm with a knowledgeable provider.
How to Use This List in Practice
Carry documentation. Maintain a written or digital record of your G6PD status, your specific variant if known, and this drug list. Medical alert cards and apps are available to store this information accessibly.
Disclose at every encounter. Inform every physician, urgent care provider, pharmacist, dentist, and emergency room clinician of your G6PD deficiency before any medication is prescribed or administered.
Ask before accepting. When prescribed a new medication, ask your pharmacist to cross-reference it with G6PD safety resources. Pharmacists are trained to flag these interactions.
Do not self-discontinue. If you are already taking a medication on this list, do not stop without medical supervision. The risks of abruptly stopping some medications may outweigh the G6PD-related risk in certain clinical contexts.
Advocate in emergencies. In an emergency setting, G6PD status can be overlooked. Wearing a medical ID bracelet and ensuring a family member or caregiver can communicate your condition is a critical safety measure.
A Note on Evolving Research
Drug safety classifications for G6PD patients are not static. Research continues to refine our understanding of which drugs carry risk for which variants and at what doses. The WHO has revised its G6PD drug risk classifications in recent years, and the FDA continues to update labeling requirements as new evidence emerges.
Patients and caregivers are encouraged to consult current resources from organizations such as the National Institutes of Health (NIH), the American Society of Hematology, and the G6PD Deficiency Association, and to work with hematologists or geneticists who are familiar with the evolving evidence base.
Living with G6PD deficiency requires vigilance — but vigilance built on knowledge is empowering, not paralyzing. By understanding which drugs pose risk, communicating clearly with your healthcare team, and staying informed as the science evolves, G6PD patients can navigate the medical landscape with confidence and safety.
